565results about "Isotope introduction to acyclic/carbocyclic compounds" patented technology

The present invention relates to a method for deuteration of a compound having an aromatic ring, using an activated catalyst, and the method comprises reacting a compound having an aromatic ring with heavy hydrogen source in the presence of an activated catalyst selected from a platinum catalyst, a rhodium catalyst, a ruthenium catalyst, a nickel catalyst and a cobalt catalyst.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[¹⁸F]fluorocyclobutyl-1-carboxylic acid (2-[¹⁸F]FACBC) and 1-amino-2-[¹⁸F]fluoromethylcyclobutyl-1-carboxylic acid (2-[¹⁸F]FMACBC). The labeled amino acid compounds of the invention are useful as imaging agents in detecting and/or monitoring tumors in a subject by PET or SPECT.

Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

The invention provides a nitrogen-containing compound shown as a chemical formula I, an electronic element and an electronic device, and belongs to the technical field of organic materials. The nitrogen-containing compound can improve the performance of an electronic component. The structure represented as the specification refers to a chemical bond, wherein R1 and R2 are respectively and independently selected from hydrogen and a group shown as a chemical formula 1-1, and only one of R1 and R2 is a group shown as a chemical formula 1-1; when R1 or R2 is selected from hydrogen, R1 or R2 selected from hydrogen can be substituted by R4.

Disclosed are compounds that are anandamide transport inhibitors and their pharmacological use.

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with ¹⁸F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

The present invention provides a method for the preparation of radioisotopically-labelled imaging agent compositions. The method uses precursors which are bound to soluble polymers, so that the radiolabelling reaction is carried out in solution. Also described are radiopharmaceutical compositions, automated versions of the radiolabelling method and disposable cassettes for use in the automated method.

An anthracene derivative represented by Formula 1 is disclosed. An organic light-emitting device including an anode, a cathode, and an organic layer between the anode and the cathode, where the organic layer includes at least one anthracene derivative represented by Formula 1, is also disclosed. A method of manufacturing the organic light-emitting device is also disclosed.

The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in ¹⁸F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

Provided is a compound of formula (I):

or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

The invention relates to a boron carrying agent for integrating tumor diagnosis and treatment. The boron carrying agent is tyrosine boron trifluoride (FBY) obtained by replacing a carboxyl group witha boron trifluoride group on the basis of tyrosine. FBY can be used for boron neutron capture therapy (BNCT) for treating malignant tumors; radioactive <18>F-labeled FBY can also be used for positronemission tomography (PET) imaging diagnosis. <18F>-FBY can simultaneously achieve imaging diagnosis and precise treatment of cancers.

The invention provides a photocatalytic halohydrocarbon dehalogenation conversion method which comprises the following steps: adding a photocatalyst quantum dot/rod into a solvent to obtain a solutionA; adding halohydrocarbon and an electronic sacrificial body into the solution A to obtain a solution B; utilizing a light source to irradiate the solution B and catalyzing the solution B to performhalohydrocarbon dehalogenation conversion. According to the photocatalytic halohydrocarbon dehalogenation conversion method disclosed by the invention, a nano quantum dot and a nano quantum rod are applied to dehalogenation conversion reaction of alkyl halide, alkenyl halide and alkyne halide for the first time; the reaction conditions are moderate, visible light is utilized as driving energy, a product is hydrocarbon compound, and the whole process has the advantages of environmental protection, conciseness and high efficiency. In addition, higher hydrocarbon of carbon chain growth can be generated after dehalogenation reaction, so that the method has potential application in preparation of higher hydrocarbon. According to the method disclosed by the invention, halohydrocarbon dehalogenation conversion and deuteration marking processes are jointly performed; hydrocarbon deuteration marking can be finished when a halohydrocarbon dehalogenation process is finished. The invention furtherprovides a method for performing deuteration marking on hydrocarbon.

The present invention relates to connections which are suitable for use in electronic devices, preferably organic electroluminescence devices.